This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Perspective

Aug. 28, 2014

Life science firms must adjust to new normal

Patenting strategies in the life sciences must pivot to accommodate two recent U.S. Supreme Court decisions interpreting what subject matter is eligible for patent protection. By Antoinette Konski


By Antoinette Konski

Patenting strategies in the life sciences must pivot to accommodate two recent U.S. Supreme Court decisions interpreting what subject matter is eligible for patent protection. In less than two years' time, the decisions in Mayo Collaborative Services v. Prometheus Laboratories Inc. (2012) and Ass'n for Molecular Pathology v. Myriad Genetics Inc. (2013) removed from patent-eligibility inventions t...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up